# Grace Kong

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/grace-kong/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,962 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 40 |
| i10-index | 75 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5002564826 |
| ORCID iD | 0000-0002-0834-6888 |
| Works | 153 |

## Researcher papers

- [\[177Lu\]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study](https://scholariq.org/papers/177lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration/)
- [Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/)
- [Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/long-term-follow-up-and-outcomes-of-retreatment-in-an-expanded-50-patient-single/)
- [PSMA and FDG-PET as predictive and prognostic biomarkers in patients given \[177Lu\]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial](https://scholariq.org/papers/psma-and-fdg-pet-as-predictive-and-prognostic-biomarkers-in-patients-given-177lu/)
- [High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours](https://scholariq.org/papers/high-management-impact-of-ga-68-dotatate-gatate-pet-ct-for-imaging/)
- [Overall survival with \[177Lu\]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial](https://scholariq.org/papers/overall-survival-with-177lu-lu-psma-617-versus-cabazitaxel-in-metastatic/)
- [68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity](https://scholariq.org/papers/68ga-dotatate-and-18f-fdg-pet-ct-in-paraganglioma-and-pheochromocytoma-utility/)
- [Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy](https://scholariq.org/papers/poor-outcomes-for-patients-with-metastatic-castration-resistant-prostate-cancer/)
- [Course of Depressive Symptoms and Medication Adherence After Acute Coronary Syndromes](https://scholariq.org/papers/course-of-depressive-symptoms-and-medication-adherence-after-acute-coronary/)
- [Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma](https://scholariq.org/papers/efficacy-of-peptide-receptor-radionuclide-therapy-for-functional-metastatic/)
- [Early Outcomes of Surgery for Carcinoid Heart Disease](https://scholariq.org/papers/early-outcomes-of-surgery-for-carcinoid-heart-disease/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.